IBIO vs MCK · rev $100.0K vs P/E 20, rev $403.43B
iBio, Inc. Common Stock (IBIO) versus McKesson Corporation (MCK) — a side-by-side from cached financials, not a winner call.
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
McKesson Corporation (MCK) is a medical distribution company listed on NYSE.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
Latest reported MCK revenue for 2026-03-31 was $403.43B. Net income was $4.76B. Revenue was up 12.4% from 2025-03-31 to 2026-03-31. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
IBIO currently screens at market cap $13.4M. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
Not investment advice. Open the IBIO and MCK stock pages for the full models.
Not investment advice.